Pharmaceutical Generics, Vertical Product Differentiation, and Public Policy
UPF Working Paper No. 662
23 Pages Posted: 3 Jun 2003
Date Written: January 2003
Abstract
This paper studies oligopolistic competition in off-patent pharmaceutical markets using a vertical product differentiation model. This model can explain the observation that countries with stronger regulations have smaller generic market shares. It can also explain the differences in observed regulatory regimes. Stronger regulation may be due to a higher proportion of production that is done by foreign firms. Finally, a closely related model can account for the observed increase in prices by patent owners after entry of generic producers. differentiation
Keywords: Pharmaceutical industry, generics, vertical product
JEL Classification: I10, I18, L18, L65
Suggested Citation: Suggested Citation
Do you have a job opening that you would like to promote on SSRN?
Recommended Papers
-
Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation?
By Kurt Richard Brekke, Astrid Grasdal, ...
-
Reference Pricing of Pharmaceuticals
By Kurt Richard Brekke, Ingrid Königbauer, ...
-
European Pharmaceutical Price Regulation, Firm Profitability, and R&D Spending
By Joseph H. Golec and John A. Vernon
-
European Pharmaceutical Price Regulation, Firm Profitability, and R&D Spending
By Joseph H. Golec and John A. Vernon
-
By Kurt Richard Brekke, Tor Helge Holmas, ...
-
The Simple Economics of Risk-Sharing Agreements between the NHS and the Pharmaceutical Industry
-
Competition and the Reference Pricing Scheme for Pharmaceuticals
-
Competition and the Reference Pricing Scheme for Pharmaceuticals
-
Patents, Price Regulation and Innovation in the Pharmaceutical Industry
-
Margins and Market Shares: Pharmacy Incentives for Generic Substitution
By Kurt Richard Brekke, Tor Helge Holmas, ...